Literature DB >> 31597196

International trends in hepatocellular carcinoma incidence, 1978-2012.

Jessica L Petrick1,2, Andrea A Florio1, Ariana Znaor3, David Ruggieri4, Mathieu Laversanne3, Christian S Alvarez1, Jacques Ferlay3, Patricia C Valery5, Freddie Bray3, Katherine A McGlynn1.   

Abstract

Primary liver cancer, the major histology of which is hepatocellular carcinoma (HCC), is the second leading cause of cancer death worldwide. We comprehensively examined recent international trends of primary liver cancer and HCC incidence using population-based cancer registry data. Incidence for all primary liver cancer and for HCC by calendar time and birth cohort was examined for selected countries between 1978 and 2012. For each successive 5-year period, age-standardized incidence rates were calculated from Volumes V to XI of the Cancer Incidence in Five Continents (CI5) series using the online electronic databases, CI5plus. Large variations persist in liver cancer incidence globally. Rates of liver cancer remain highest in Asian countries, specifically in the East and South-East, and Italy. However, rates in these high-risk countries have been decreasing in recent years. Rates in India and in most countries of Europe, the Americas and Oceania are rising. As the population seroprevalence of hepatitis B virus (HBV) continues to decline, we anticipate rates of HCC in many high-risk countries will continue to decrease. Treatment of hepatitis C virus (HCV) is likely to bring down rates further in some high-rate, as well as low-rate, countries with access to effective therapies. However, such gains in the control of liver cancer are at risk of being reversed by the growing obesity and diabetes epidemics, suggesting diabetes treatment and primary prevention of obesity will be key in reducing liver cancer in the longer-term. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  cancer registry; epidemiology; incidence rates; liver cancer

Mesh:

Year:  2019        PMID: 31597196      PMCID: PMC7470451          DOI: 10.1002/ijc.32723

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  42 in total

Review 1.  Obesity in Asia--is it different from rest of the world.

Authors:  Ambady Ramachandran; Snehalatha Chamukuttan; Samith A Shetty; Nanditha Arun; Priscilla Susairaj
Journal:  Diabetes Metab Res Rev       Date:  2012-12       Impact factor: 4.876

2.  Models for temporal variation in cancer rates. I: Age-period and age-cohort models.

Authors:  D Clayton; E Schifflers
Journal:  Stat Med       Date:  1987-06       Impact factor: 2.373

3.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

Review 4.  Epidemic obesity and type 2 diabetes in Asia.

Authors:  Kun-Ho Yoon; Jin-Hee Lee; Ji-Won Kim; Jae Hyoung Cho; Yoon-Hee Choi; Seung-Hyun Ko; Paul Zimmet; Ho-Young Son
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

Review 5.  New trends on obesity and NAFLD in Asia.

Authors:  Jian-Gao Fan; Seung-Up Kim; Vincent Wai-Sun Wong
Journal:  J Hepatol       Date:  2017-06-19       Impact factor: 25.083

6.  Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China.

Authors:  Zongtang Sun; Taoyang Chen; Snorri S Thorgeirsson; Qimin Zhan; Jianguo Chen; Ju-Hyun Park; Peixin Lu; Chu Chieh Hsia; Nengjin Wang; Libin Xu; Lingling Lu; Fei Huang; Yuanrong Zhu; Jianhua Lu; Zhengping Ni; Qinan Zhang; Yuying Wu; Guoting Liu; Zhiyuan Wu; Chunfeng Qu; Mitchell H Gail
Journal:  Carcinogenesis       Date:  2013-01-14       Impact factor: 4.944

7.  Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China.

Authors:  Jian-Guo Chen; Patricia A Egner; Derek Ng; Lisa P Jacobson; Alvaro Muñoz; Yuan-Rong Zhu; Geng-Sun Qian; Felicia Wu; Jian-Min Yuan; John D Groopman; Thomas W Kensler
Journal:  Cancer Prev Res (Phila)       Date:  2013-08-20

8.  Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.

Authors:  Oxana V Makarova-Rusher; Sean F Altekruse; Tim S McNeel; Susanna Ulahannan; Austin G Duffy; Barry I Graubard; Tim F Greten; Katherine A McGlynn
Journal:  Cancer       Date:  2016-03-21       Impact factor: 6.860

9.  The changing epidemiology of primary liver cancer.

Authors:  Jessica L Petrick; Katherine A McGlynn
Journal:  Curr Epidemiol Rep       Date:  2019-05-03

10.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.

Authors:  Tomi Akinyemiju; Semaw Abera; Muktar Ahmed; Noore Alam; Mulubirhan Assefa Alemayohu; Christine Allen; Rajaa Al-Raddadi; Nelson Alvis-Guzman; Yaw Amoako; Al Artaman; Tadesse Awoke Ayele; Aleksandra Barac; Isabela Bensenor; Adugnaw Berhane; Zulfiqar Bhutta; Jacqueline Castillo-Rivas; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Lalit Dandona; Rakhi Dandona; Subhojit Dey; Daniel Dicker; Huyen Phuc; Donatus U. Ekwueme; Maysaa El Sayed Zaki; Florian Fischer; Thomas Fürst; Jamie Hancock; Simon I. Hay; Peter Hotez; Sun Ha Jee; Amir Kasaeian; Yousef Khader; Young-Ho Khang; Anil Kumar; Michael Kutz; Heidi Larson; Alan Lopez; Raimundas Lunevicius; Reza Malekzadeh; Colm McAlinden; Toni Meier; Walter Mendoza; Ali Mokdad; Maziar Moradi-Lakeh; Gabriele Nagel; Quyen Nguyen; Grant Nguyen; Felix Ogbo; George Patton; David M. Pereira; Farshad Pourmalek; Mostafa Qorbani; Amir Radfar; Gholamreza Roshandel; Joshua A Salomon; Juan Sanabria; Benn Sartorius; Maheswar Satpathy; Monika Sawhney; Sadaf Sepanlou; Katya Shackelford; Hirbo Shore; Jiandong Sun; Desalegn Tadese Mengistu; Roman Topór-Mądry; Bach Tran; Vasiliy Vlassov; Stein Emil Vollset; Theo Vos; Tolassa Wakayo; Elisabete Weiderpass; Andrea Werdecker; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Zoubida Zaidi; Liguo Zhu; Christopher J. L. Murray; Mohsen Naghavi; Christina Fitzmaurice
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

View more
  68 in total

Review 1.  Frontiers of therapy for hepatocellular carcinoma.

Authors:  Michael Heller; Neehar D Parikh; Nicholas Fidelman; Dawn Owen
Journal:  Abdom Radiol (NY)       Date:  2021-04-10

Review 2.  Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve.

Authors:  S Z Frager; J M Schwartz
Journal:  Curr Oncol       Date:  2020-11-01       Impact factor: 3.677

3.  Th22/IL-22 mediates the progression of HBV-related hepatocellular carcinoma via STAT3.

Authors:  Jia Zhang; Zhou Liu; Lingpeng Liu; Mingwen Huang; Yong Huang
Journal:  Cytotechnology       Date:  2022-02-22       Impact factor: 2.058

Review 4.  Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update.

Authors:  Maher Hendi; Yiping Mou; Jiemin Lv; Bin Zhang; Xiujun Cai
Journal:  Gastrointest Tumors       Date:  2021-07-15

5.  The effect of PPP2CA expression on the prognosis of patients with hepatocellular carcinoma and its molecular biological characteristics.

Authors:  Jingchang Liang; Yu Huang; Yumei Zhang; Zhiming Zhang; Chenglei Yang; Shen Huang; Jinlong Xie; Xiang Nong; Jianyong Liu
Journal:  J Gastrointest Oncol       Date:  2021-12

6.  Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis.

Authors:  Junjie Huang; Veeleah Lok; Chun Ho Ngai; Cedric Chu; Harsh K Patel; Viveksandeep Thoguluva Chandraseka; Lin Zhang; Ping Chen; Shanjuan Wang; Xiang-Qian Lao; Lap Ah Tse; Wanghong Xu; Zhi-Jie Zheng; Martin C S Wong
Journal:  Liver Cancer       Date:  2021-03-30       Impact factor: 11.740

Review 7.  LI-RADS treatment response assessment of combination locoregional therapy for HCC.

Authors:  Marielia Gerena; Christopher Molvar; Mark Masciocchi; Sadhna Nandwana; Carl Sabottke; Bradley Spieler; Rishi Sharma; Leo Tsai; Ania Kielar
Journal:  Abdom Radiol (NY)       Date:  2021-06-13

8.  ABO blood groups and liver cancer: prospective results from an HBsAg cohort study.

Authors:  Ling-Ling Lu; Yong-Hui Zhang; Mei-Hua Yao; Jian-Hua Lu; Yong-Sheng Chen; Jun Xu; Jian Zhu; Hai-Zhen Chen; Jian-Guo Chen
Journal:  BMJ Open       Date:  2021-05-11       Impact factor: 2.692

Review 9.  Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications.

Authors:  Nguyen H Tran
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

10.  Inactivators of Ornithine Aminotransferase for the Treatment of Hepatocellular Carcinoma.

Authors:  Richard B Silverman
Journal:  ACS Med Chem Lett       Date:  2021-12-09       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.